Irbesartan Tetrafarma

Irbesartan, the active ingredient in Irbesartan Tetrafarma, is an angiotensin II receptor blocker presented as an oral dosage form for oral use. Originating from the European Union market, it is employed to lower high blood pressure and to protect kidney function in patients with diabetic nephropathy. The product complies with EU regulatory requirements and is manufactured under strict quality controls.

GNH USA supplies Irbesartan Tetrafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality manufacturing standards and reliable distribution across global markets.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to control blood pressure and renal disease progression.

- Hypertension: Reduces systolic and diastolic blood pressure in patients with elevated readings. - Diabetic nephropathy: Slows the decline of kidney function in individuals with diabetes‑related kidney disease. - Chronic kidney disease associated with diabetes: Provides renal protection by decreasing proteinuria and preserving glomerular filtration rate.

Common side effects are generally mild and reversible.

Common Side Effects: - Dizziness: Light‑headed sensation, especially after standing. - Headache: Mild to moderate cranial discomfort. - Fatigue: Generalized tiredness without exertion. - Abdominal pain: Mild stomach discomfort. - Hyperkalemia: Elevated blood potassium levels.

Serious or Rare Side Effects: - Angioedema: Swelling of face, lips, tongue, or airway. - Severe hypotension: Marked drop in blood pressure causing faintness. - Acute renal failure: Sudden loss of kidney function. - Hepatic injury: Elevated liver enzymes or hepatitis.

Patients should be monitored for safety and appropriate use. - Blood pressure monitoring: Check regularly to avoid excessive lowering. - Renal function assessment: Evaluate serum creatinine and eGFR before and during therapy. - Serum potassium measurement: Monitor for hyperkalemia, especially with concomitant potassium‑sparing agents. - Pregnancy and lactation: Use only if clearly needed; discuss risks with a healthcare professional. - Store at ambient temperature: Keep below 25°C in the original packaging, protect from moisture.

Irbesartan may interact with several drug classes, requiring caution.

Major Interactions (Avoid): - ACE inhibitors: Combined use increases risk of hyperkalemia and renal impairment. - Aliskiren (in diabetes): May cause severe hypotension and renal dysfunction. - Potassium‑sparing diuretics: Heightens risk of dangerous hyperkalemia. - NSAIDs: Can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Diuretics: May enhance initial blood pressure lowering; monitor electrolytes. - Lithium: Irbesartan can increase lithium levels; check serum concentrations. - Other antihypertensives: Additive blood pressure reduction; adjust doses as needed. - NSAIDs (monitor): May affect renal function; observe kidney markers.